{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T11:55:43Z","timestamp":1770292543067,"version":"3.49.0"},"reference-count":151,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2013,4,26]],"date-time":"2013-04-26T00:00:00Z","timestamp":1366934400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s10096-013-1876-y","type":"journal-article","created":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T23:43:25Z","timestamp":1367451805000},"page":"1231-1252","source":"Crossref","is-referenced-by-count":101,"title":["Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review"],"prefix":"10.1007","volume":"32","author":[{"given":"M. C.","family":"Gaspar","sequence":"first","affiliation":[]},{"given":"W.","family":"Couet","sequence":"additional","affiliation":[]},{"given":"J.-C.","family":"Olivier","sequence":"additional","affiliation":[]},{"given":"A. A. C. C.","family":"Pais","sequence":"additional","affiliation":[]},{"given":"J. J. S.","family":"Sousa","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2013,4,26]]},"reference":[{"issue":"1","key":"1876_CR1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1741-7015-9-32","volume":"9","author":"N H\u00f8iby","year":"2011","unstructured":"H\u00f8iby N (2011) Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med 9(1):32\u201338. doi: 10.1186\/1741-7015-9-32","journal-title":"BMC Med"},{"issue":"1","key":"1876_CR2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1183\/09031936.03.00057003","volume":"23","author":"RC Boucher","year":"2004","unstructured":"Boucher RC (2004) New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 23(1):146\u2013158. doi: 10.1183\/09031936.03.00057003","journal-title":"Eur Respir J"},{"issue":"4","key":"1876_CR3","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1034\/j.1399-3003.2000.16d30.x","volume":"16","author":"G D\u00f6ring","year":"2000","unstructured":"D\u00f6ring G, Conway SP, Heijerman HG, Hodson ME, H\u00f8iby N, Smyth A, Touw DJ (2000) Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 16(4):749\u2013767","journal-title":"Eur Respir J"},{"issue":"4","key":"1876_CR4","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1517\/17425247.2011.561310","volume":"8","author":"BM Ibrahim","year":"2011","unstructured":"Ibrahim BM, Tsifansky MD, Yang Y, Yeo Y (2011) Challenges and advances in the development of inhalable drug formulations for cystic fibrosis lung disease. Expert Opin Drug Deliv 8(4):451\u2013466. doi: 10.1517\/17425247.2011.561310","journal-title":"Expert Opin Drug Deliv"},{"issue":"3","key":"1876_CR5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1056\/NEJM199607183350307","volume":"335","author":"BW Ramsey","year":"1996","unstructured":"Ramsey BW (1996) Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 335(3):179\u2013188. doi: 10.1056\/NEJM199607183350307","journal-title":"N Engl J Med"},{"issue":"Suppl 6","key":"1876_CR6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0300-2896(11)70030-8","volume":"47","author":"RM Gir\u00f3n Moreno","year":"2011","unstructured":"Gir\u00f3n Moreno RM, Salcedo Posadas A, Mar G\u00f3mez-Punter R (2011) Inhaled antibiotic therapy in cystic fibrosis (Antibioterapia inhalada en la fibrosis quistica). Arch Bronconeumol 47(Suppl 6):14\u201318","journal-title":"Arch Bronconeumol"},{"issue":"6","key":"1876_CR7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jcf.2011.06.014","volume":"10","author":"GB Rogers","year":"2011","unstructured":"Rogers GB, Hoffman LR, D\u00f6ring G (2011) Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis. J Cyst Fibros 10(6):387\u2013400. doi: 10.1016\/j.jcf.2011.06.014","journal-title":"J Cyst Fibros"},{"issue":"2","key":"1876_CR8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1574-6968.2009.01704.x","volume":"300","author":"AM George","year":"2009","unstructured":"George AM, Jones PM, Middleton PG (2009) Cystic fibrosis infections: treatment strategies and prospects. FEMS Microbiol Lett 300(2):153\u2013164. doi: 10.1111\/j.1574-6968.2009.01704.x","journal-title":"FEMS Microbiol Lett"},{"issue":"1","key":"1876_CR9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1146\/annurev.med.58.071905.105316","volume":"58","author":"RC Boucher","year":"2007","unstructured":"Boucher RC (2007) Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med 58(1):157\u2013170. doi: 10.1146\/annurev.med.58.071905.105316","journal-title":"Annu Rev Med"},{"issue":"5","key":"1876_CR10","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4187\/aarc0492","volume":"54","author":"JC Davies","year":"2009","unstructured":"Davies JC, Bilton D (2009) Bugs, biofilms, and resistance in cystic fibrosis. Respir Care 54(5):628\u2013640","journal-title":"Respir Care"},{"issue":"1","key":"1876_CR11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1089\/jamp.2007.0659","volume":"21","author":"MA Mall","year":"2008","unstructured":"Mall MA (2008) Role of cilia, mucus, and airway surface liquid in mucociliary dysfunction: lessons from mouse models. J Aerosol Med Pulm Drug Deliv 21(1):13\u201324. doi: 10.1089\/jamp.2007.0659","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"1","key":"1876_CR12","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1164\/ajrccm.156.1.9606123","volume":"156","author":"E Deneuville","year":"1997","unstructured":"Deneuville E, Perrot-Minot C, Pennaforte F, Roussey M, Zahm JM, Clavel C, Puchelle E, de Bentzmann S (1997) Revisited physicochemical and transport properties of respiratory mucus in genotyped cystic fibrosis patients. Am J Respir Crit Care Med 156(1):166\u2013172","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"1876_CR13","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3233\/BIR-1987-24611","volume":"24","author":"M King","year":"1987","unstructured":"King M (1987) The role of mucus viscoelasticity in cough clearance. Biorheology 24(6):589\u2013597","journal-title":"Biorheology"},{"issue":"6","key":"1876_CR14","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.copbio.2008.11.002","volume":"19","author":"MN Dudley","year":"2008","unstructured":"Dudley MN, Loutit J, Griffith DC (2008) Aerosol antibiotics: considerations in pharmacological and clinical evaluation. Curr Opin Biotechnol 19(6):637\u2013643. doi: 10.1016\/j.copbio.2008.11.002","journal-title":"Curr Opin Biotechnol"},{"issue":"26","key":"1876_CR15","doi-asserted-by":"crossref","first-page":"16083","DOI":"10.1073\/pnas.2634339100","volume":"100","author":"RD Coakley","year":"2003","unstructured":"Coakley RD, Grubb BR, Paradiso AM, Gatzy JT, Johnson LG, Kreda SM, O\u2019Neal WK, Boucher RC (2003) Abnormal surface liquid pH regulation by cultured cystic fibrosis bronchial epithelium. Proc Natl Acad Sci U S A 100(26):16083\u201316088. doi: 10.1073\/pnas.2634339100","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1876_CR16","doi-asserted-by":"crossref","first-page":"658","DOI":"10.4187\/aarc0537","volume":"54","author":"DE Geller","year":"2009","unstructured":"Geller DE (2009) Aerosol antibiotics in cystic fibrosis. Respir Care 54(5):658\u2013670","journal-title":"Respir Care"},{"issue":"Suppl 2","key":"1876_CR17","doi-asserted-by":"crossref","first-page":"S146","DOI":"10.1016\/S1569-1993(11)60019-2","volume":"10","author":"R Bals","year":"2011","unstructured":"Bals R, Hubert D, T\u00fcmmler B (2011) Antibiotic treatment of CF lung disease: from bench to bedside. J Cyst Fibros 10(Suppl 2):S146\u2013S151. doi: 10.1016\/s1569-1993(11)60019-2","journal-title":"J Cyst Fibros"},{"issue":"5","key":"1876_CR18","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jcf.2011.06.002","volume":"10","author":"CH Goss","year":"2011","unstructured":"Goss CH, Muhlebach MS (2011) Review: Staphylococcus aureus and MRSA in cystic fibrosis. J Cyst Fibros 10(5):298\u2013306. doi: 10.1016\/j.jcf.2011.06.002","journal-title":"J Cyst Fibros"},{"issue":"6","key":"1876_CR19","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/11316240-000000000-00000","volume":"12","author":"M Westreenen van","year":"2010","unstructured":"van Westreenen M, Tiddens HAWM (2010) New antimicrobial strategies in cystic fibrosis. Paediatr Drugs 12(6):343\u2013352","journal-title":"Paediatr Drugs"},{"issue":"4","key":"1876_CR20","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1099\/mic.0.2006\/004077-0","volume":"153","author":"F Harrison","year":"2007","unstructured":"Harrison F (2007) Microbial ecology of the cystic fibrosis lung. Microbiology 153(4):917\u2013923. doi: 10.1099\/mic.0.2006\/004077-0","journal-title":"Microbiology"},{"issue":"4","key":"1876_CR21","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.prrv.2010.07.003","volume":"11","author":"AMM Vrankrijker de","year":"2010","unstructured":"de Vrankrijker AMM, Wolfs TFW, van der Ent CK (2010) Challenging and emerging pathogens in cystic fibrosis. Paediatr Respir Rev 11(4):246\u2013254. doi: 10.1016\/j.prrv.2010.07.003","journal-title":"Paediatr Respir Rev"},{"issue":"7","key":"1876_CR22","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1128\/AAC.01845-09","volume":"54","author":"ME Grinwis","year":"2010","unstructured":"Grinwis ME, Sibley CD, Parkins MD, Eshaghurshan CS, Rabin HR, Surette MG (2010) Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients. Antimicrob Agents Chemother 54(7):2823\u20132829. doi: 10.1128\/aac.01845-09","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"1876_CR23","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jcf.2012.10.004","volume":"11","author":"G D\u00f6ring","year":"2012","unstructured":"D\u00f6ring G, Flume P, Heijerman H, Elborn JS; Consensus Study Group (2012) Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 11(6):461\u2013479. doi: 10.1016\/j.jcf.2012.10.004","journal-title":"J Cyst Fibros"},{"issue":"4","key":"1876_CR24","doi-asserted-by":"crossref","first-page":"e36313","DOI":"10.1371\/journal.pone.0036313","volume":"7","author":"L Delhaes","year":"2012","unstructured":"Delhaes L, Monchy S, Fr\u00e9alle E, Hubans C, Salleron J, Leroy S, Prevotat A, Wallet F, Wallaert B, Dei-Cas E, Sime-Ngando T, Chab\u00e9 M, Viscogliosi E (2012) The airway microbiota in cystic fibrosis: a complex fungal and bacterial community\u2014implications for therapeutic management. PLoS One 7(4):e36313. doi: 10.1371\/journal.pone.0036313","journal-title":"PLoS One"},{"issue":"7","key":"1876_CR25","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2217\/fmb.12.55","volume":"7","author":"DR VanDevanter","year":"2012","unstructured":"VanDevanter DR, LiPuma JJ (2012) Microbial diversity in the cystic fibrosis airways: where is thy sting? Future Microbiol 7(7):801\u2013803. doi: 10.2217\/fmb.12.55","journal-title":"Future Microbiol"},{"issue":"3","key":"1876_CR26","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MOP.0b013e32834604f2","volume":"23","author":"ET Zemanick","year":"2011","unstructured":"Zemanick ET, Sagel SD, Harris JK (2011) The airway microbiome in cystic fibrosis and implications for treatment. Curr Opin Pediatr 23(3):319\u2013324. doi: 10.1097\/MOP.0b013e32834604f2","journal-title":"Curr Opin Pediatr"},{"key":"1876_CR27","doi-asserted-by":"crossref","unstructured":"Lynch SV, Bruce KD (2013) The cystic fibrosis airway microbiome. Cold Spring Harb Perspect Med. 3(3). pii: a009738. doi: 10.1101\/cshperspect.a009738","DOI":"10.1101\/cshperspect.a009738"},{"issue":"5","key":"1876_CR28","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2165\/00003495-200060050-00006","volume":"60","author":"D Banerjee","year":"2000","unstructured":"Banerjee D, Stableforth D (2000) The treatment of respiratory Pseudomonas infection in cystic fibrosis: what drug and which way? Drugs 60(5):1053\u20131064","journal-title":"Drugs"},{"issue":"6","key":"1876_CR29","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/00063198-200311000-00008","volume":"9","author":"M Rosenfeld","year":"2003","unstructured":"Rosenfeld M, Ramsey BW, Gibson RL (2003) Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management. Curr Opin Pulm Med 9(6):492\u2013497","journal-title":"Curr Opin Pulm Med"},{"issue":"11","key":"1876_CR30","doi-asserted-by":"crossref","first-page":"e50731","DOI":"10.1371\/journal.pone.0050731","volume":"7","author":"N Cramer","year":"2012","unstructured":"Cramer N, Wiehlmann L, Ciofu O, Tamm S, H\u00f8iby N, T\u00fcmmler B (2012) Molecular epidemiology of chronic Pseudomonas aeruginosa airway infections in cystic fibrosis. PLoS One 7(11):e50731. doi: 10.1371\/journal.pone.0050731","journal-title":"PLoS One"},{"issue":"3","key":"1876_CR31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jcf.2004.03.010","volume":"3","author":"S Campana","year":"2004","unstructured":"Campana S, Taccetti G, Ravenni N, Masi I, Audino S, Sisi B, Repetto T, D\u00f6ring G, de Martino M (2004) Molecular epidemiology of Pseudomonas aeruginosa, Burkholderia cepacia complex and methicillin-resistant Staphylococcus aureus in a cystic fibrosis center. J Cyst Fibros 3(3):159\u2013163. doi: 10.1016\/j.jcf.2004.03.010","journal-title":"J Cyst Fibros"},{"issue":"1","key":"1876_CR32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1569-1993(02)00141-8","volume":"2","author":"TWR Lee","year":"2003","unstructured":"Lee TWR, Brownlee KG, Conway SP, Denton M, Littlewood JM (2003) Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cystic Fibros 2(1):29\u201334. doi: 10.1016\/s1569-1993(02)00141-8","journal-title":"J Cystic Fibros"},{"issue":"2","key":"1876_CR33","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1099\/jmm.0.023838-0","volume":"60","author":"T Billard-Pomares","year":"2011","unstructured":"Billard-Pomares T, Herwegh S, Wizla-Derambure N, Turck D, Courcol R, Husson M-O (2011) Application of quantitative PCR to the diagnosis and monitoring of Pseudomonas aeruginosa colonization in 5\u201318-year-old cystic fibrosis patients. J Med Microbiol 60(2):157\u2013161. doi: 10.1099\/jmm.0.023838-0","journal-title":"J Med Microbiol"},{"issue":"5","key":"1876_CR34","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jcf.2011.05.004","volume":"10","author":"P Deschaght","year":"2011","unstructured":"Deschaght P, Van Daele S, De Baets F, Vaneechoutte M (2011) PCR and the detection of Pseudomonas aeruginosa in respiratory samples of CF patients. A literature review. J Cyst Fibros 10(5):293\u2013297. doi: 10.1016\/j.jcf.2011.05.004","journal-title":"J Cyst Fibros"},{"issue":"3","key":"1876_CR35","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.vaccine.2009.10.080","volume":"28","author":"D Bumann","year":"2010","unstructured":"Bumann D, Behre C, Behre K, Herz S, Gewecke B, Gessner JE, von Specht BU, Baumann U (2010) Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: a clinical trial of immunogenicity in lower airways of human volunteers. Vaccine 28(3):707\u2013713. doi: 10.1016\/j.vaccine.2009.10.080","journal-title":"Vaccine"},{"issue":"26","key":"1876_CR36","doi-asserted-by":"crossref","first-page":"11020","DOI":"10.1073\/pnas.0702403104","volume":"104","author":"G D\u00f6ring","year":"2007","unstructured":"D\u00f6ring G, Meisner C, Stern M; Flagella Vaccine Trial Study Group (2007) A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc Natl Acad Sci USA 104(26):11020\u201311025. doi: 10.1073\/pnas.0702403104","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"1876_CR37","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ijantimicag.2009.12.011","volume":"35","author":"N H\u00f8iby","year":"2010","unstructured":"H\u00f8iby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O (2010) Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents 35(4):322\u2013332. doi: 10.1016\/j.ijantimicag.2009.12.011","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"1876_CR38","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1128\/JB.153.1.281-285.1983","volume":"153","author":"TI Nicas","year":"1983","unstructured":"Nicas TI, Hancock REW (1983) Pseudomonas aeruginosa outer membrane permeability: isolation of a porin protein F-deficient mutant. J Bacteriol 153(1):281\u2013285","journal-title":"J Bacteriol"},{"issue":"11","key":"1876_CR39","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1128\/AAC.32.11.1636","volume":"32","author":"SC Aronoff","year":"1988","unstructured":"Aronoff SC (1988) Outer membrane permeability in Pseudomonas cepacia: diminished porin content in a beta-lactam-resistant mutant and in resistant cystic fibrosis isolates. Antimicrob Agents Chemother 32(11):1636\u20131639","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1876_CR40","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1128\/AAC.33.2.136","volume":"33","author":"JL Burns","year":"1989","unstructured":"Burns JL, Hedin LA, Lien DM (1989) Chloramphenicol resistance in Pseudomonas cepacia because of decreased permeability. Antimicrob Agents Chemother 33(2):136\u2013141","journal-title":"Antimicrob Agents Chemother"},{"issue":"5157","key":"1876_CR41","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1126\/science.8153625","volume":"264","author":"H Nikaido","year":"1994","unstructured":"Nikaido H (1994) Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science 264(5157):382\u2013388. doi: 10.1126\/science.8153625","journal-title":"Science"},{"issue":"6","key":"1876_CR42","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1128\/AAC.01478-08","volume":"54","author":"N Gr\u00e9goire","year":"2010","unstructured":"Gr\u00e9goire N, Raherison S, Grignon C, Comets E, Marliat M, Ploy M-C, Couet W (2010) Semimechanistic pharmacokinetic\u2013pharmacodynamic model with adaptation development for time\u2013kill experiments of ciprofloxacin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 54(6):2379\u20132384. doi: 10.1128\/aac.01478-08","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1876_CR43","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.mcna.2011.03.006","volume":"95","author":"MK Bolon","year":"2011","unstructured":"Bolon MK (2011) The newer fluoroquinolones. Med Clin N Am 95(4):793\u2013817. doi: 10.1016\/j.mcna.2011.03.006","journal-title":"Med Clin N Am"},{"issue":"8\u20139","key":"1876_CR44","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0369-8114(03)00167-6","volume":"51","author":"D Hocquet","year":"2003","unstructured":"Hocquet D, El Garch F, Vogne C, Pl\u00e9siat P (2003) M\u00e9canisme de la r\u00e9sistance adaptative de Pseudomonas aeruginosa aux aminosides. Pathol Biol 51(8\u20139):443\u2013448. doi: 10.1016\/s0369-8114(03)00167-6","journal-title":"Pathol Biol"},{"issue":"11\u201312","key":"1876_CR45","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3109\/00365548.2010.509333","volume":"42","author":"G Valenza","year":"2010","unstructured":"Valenza G, Radike K, Schoen C, Horn S, Oesterlein A, Frosch M, Abele-Horn M, Hebestreit H (2010) Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment. Scand J Infect Dis 42(11\u201312):885\u2013889. doi: 10.3109\/00365548.2010.509333","journal-title":"Scand J Infect Dis"},{"issue":"2","key":"1876_CR46","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1208\/s12248-008-9033-8","volume":"10","author":"MD Tsifansky","year":"2008","unstructured":"Tsifansky MD, Yeo Y, Evgenov OV, Bellas E, Benjamin J, Kohane DS (2008) Microparticles for inhalational delivery of antipseudomonal antibiotics. AAPS J 10(2):254\u2013260. doi: 10.1208\/s12248-008-9033-8","journal-title":"AAPS J"},{"issue":"1","key":"1876_CR47","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ijantimicag.2011.08.005","volume":"39","author":"P Sonnet","year":"2012","unstructured":"Sonnet P, Izard D, Mulli\u00e9 C (2012) Prevalence of efflux-mediated ciprofloxacin and levofloxacin resistance in recent clinical isolates of Pseudomonas aeruginosa and its reversal by the efflux pump inhibitors 1-(1-naphthylmethyl)-piperazine and phenylalanine-arginine-beta-naphthylamide. Int J Antimicrob Agents 39(1):77\u201380","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"1876_CR48","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1099\/jmm.0.46884-0","volume":"55","author":"JRW Govan","year":"2006","unstructured":"Govan JRW (2006) Multidrug-resistant pulmonary infection in cystic fibrosis\u2014what does \u2018resistant\u2019 mean? J Med Microbiol 55(12):1615\u20131617. doi: 10.1099\/jmm.0.46884-0","journal-title":"J Med Microbiol"},{"issue":"9","key":"1876_CR49","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","volume":"180","author":"PA Flume","year":"2009","unstructured":"Flume PA, Mogayzel PJ Jr, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC; Clinical Practice Guidelines for Pulmonary Therapies Committee (2009) Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 180(9):802\u2013808. doi: 10.1164\/rccm.200812-1845PP","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"1876_CR50","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jac\/dkm476","volume":"61","author":"JW Mouton","year":"2008","unstructured":"Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, Cars O (2008) Tissue concentrations: do we ever learn? J Antimicrob Chemother 61(2):235\u2013237. doi: 10.1093\/jac\/dkm476","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"1876_CR51","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/jac\/12.3.281","volume":"12","author":"DM Ryan","year":"1983","unstructured":"Ryan DM, Cars O (1983) A problem in the interpretation of beta-lactam antibiotic levels in tissues. J Antimicrob Chemother 12(3):281\u2013284. doi: 10.1093\/jac\/12.3.281","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1876_CR52","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00133-06","volume":"52","author":"S Kiem","year":"2008","unstructured":"Kiem S, Schentag JJ (2008) Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother 52(1):24\u201336. doi: 10.1128\/aac.00133-06","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"1876_CR53","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1128\/AAC.40.7.1617","volume":"40","author":"JE Conte Jr","year":"1996","unstructured":"Conte JE Jr, Golden J, Duncan S, McKenna E, Lin E, Zurlinden E (1996) Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. Antimicrob Agents Chemother 40(7):1617\u20131622","journal-title":"Antimicrob Agents Chemother"},{"issue":"63","key":"1876_CR54","doi-asserted-by":"crossref","first-page":"63mr4","DOI":"10.1126\/scitranslmed.3001634","volume":"2","author":"LM Rose","year":"2010","unstructured":"Rose LM, Neale R (2010) Development of the first inhaled antibiotic for the treatment of cystic fibrosis. Sci Transl Med 2(63):63mr4. doi: 10.1126\/scitranslmed.3001634","journal-title":"Sci Transl Med"},{"issue":"1","key":"1876_CR55","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/ppul.21521","volume":"47","author":"GS Sawicki","year":"2012","unstructured":"Sawicki GS, Signorovitch JE, Zhang J, Latremouille-Viau D, von Wartburg M, Wu EQ, Shi L (2012) Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatr Pulmonol 47(1):44\u201352. doi: 10.1002\/ppul.21521","journal-title":"Pediatr Pulmonol"},{"key":"1876_CR56","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0954-6111(11)70021-X","volume":"105","author":"M Ballmann","year":"2011","unstructured":"Ballmann M, Smyth A, Geller DE (2011) Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics. Respir Med 105:S2\u2013S8","journal-title":"Respir Med"},{"issue":"3","key":"1876_CR57","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/ppul.22667","volume":"48","author":"C Stockmann","year":"2013","unstructured":"Stockmann C, Sherwin CMT, Zobell JT, Young DC, Waters CD, Spigarelli MG, Ampofo K (2013) Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones. Pediatr Pulmonol 48(3):211\u2013220. doi: 10.1002\/ppul.22667","journal-title":"Pediatr Pulmonol"},{"issue":"10","key":"1876_CR58","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/ppul.21467","volume":"46","author":"JT Zobell","year":"2011","unstructured":"Zobell JT, Young DC, Waters CD, Ampofo K, Cash J, Marshall BC, Olson J, Chatfield BA (2011) A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients. Pediatr Pulmonol 46(10):987\u2013990. doi: 10.1002\/ppul.21467","journal-title":"Pediatr Pulmonol"},{"issue":"12","key":"1876_CR59","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/ppul.22655","volume":"47","author":"JT Zobell","year":"2012","unstructured":"Zobell JT, Young DC, Waters CD, Stockmann C, Ampofo K, Sherwin CMT, Spigarelli MG (2012) Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems. Pediatr Pulmonol 47(12):1147\u20131158. doi: 10.1002\/ppul.22655","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"1876_CR60","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/ppul.22669","volume":"48","author":"JT Zobell","year":"2013","unstructured":"Zobell JT, Waters CD, Young DC, Stockmann C, Ampofo K, Sherwin CMT, Spigarelli MG (2013) Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins. Pediatr Pulmonol 48(2):107\u2013122. doi: 10.1002\/ppul.22669","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"1876_CR61","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1469-0691.2011.03667.x","volume":"18","author":"W Couet","year":"2012","unstructured":"Couet W, Gr\u00e9goire N, Marchand S, Mimoz O (2012) Colistin pharmacokinetics: the fog is lifting. Clin Microbiol Infect 18(1):30\u201339. doi: 10.1111\/j.1469-0691.2011.03667.x","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"1876_CR62","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.diagmicrobio.2009.07.018","volume":"65","author":"MS Oliveira","year":"2009","unstructured":"Oliveira MS, Prado GVB, Costa SF, Grinbaum RS, Levin AS (2009) Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. Diagn Microbiol Infect Dis 65(4):431\u2013434. doi: 10.1016\/j.diagmicrobio.2009.07.018","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"1876_CR63","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jcf.2003.12.005","volume":"3","author":"EM Westerman","year":"2004","unstructured":"Westerman EM, Le Brun PPH, Touw DJ, Frijlink HW, Heijerman HGM (2004) Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study. J Cystic Fibros 3(1):23\u201328","journal-title":"J Cystic Fibros"},{"issue":"1","key":"1876_CR64","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0939-6411(02)00044-9","volume":"54","author":"PPH Brun Le","year":"2002","unstructured":"Le Brun PPH, de Boer AH, Mannes GPM, de Fra\u0131\u0302ture DMI, Brimicombe RW, Touw DJ, Vinks AA, Frijlink HW, Heijerman HGM (2002) Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2: inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients. Eur J Pharm Biopharm 54(1):25\u201332. doi: 10.1016\/s0939-6411(02)00044-9","journal-title":"Eur J Pharm Biopharm"},{"issue":"5","key":"1876_CR65","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.ijantimicag.2008.05.010","volume":"32","author":"S Faruqi","year":"2008","unstructured":"Faruqi S, McCreanor J, Moon T, Meigh R, Morice AH (2008) Fosfomycin for Pseudomonas-related exacerbations of cystic fibrosis. Int J Antimicrob Agents 32(5):461\u2013463. doi: 10.1016\/j.ijantimicag.2008.05.010","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"1876_CR66","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1569-1993(02)00143-1","volume":"2","author":"A Mirakhur","year":"2003","unstructured":"Mirakhur A, Gallagher MJ, Ledson MJ, Hart CA, Walshaw MJ (2003) Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis. J Cystic Fibros 2(1):19\u201324. doi: 10.1016\/s1569-1993(02)00143-1","journal-title":"J Cystic Fibros"},{"issue":"3","key":"1876_CR67","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/(SICI)1099-0496(200003)29:3<210::AID-PPUL9>3.0.CO;2-2","volume":"29","author":"LE Kurlandsky","year":"2000","unstructured":"Kurlandsky LE, Fader RC (2000) In vitro activity of minocycline against respiratory pathogens from patients with cystic fibrosis. Pediatr Pulmonol 29(3):210\u2013212. doi: 10.1002\/(sici)1099-0496(200003)29:3<210::aid-ppul9>3.0.co;2\u20132","journal-title":"Pediatr Pulmonol"},{"issue":"7","key":"1876_CR68","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1128\/AAC.01797-10","volume":"55","author":"RA Keel","year":"2011","unstructured":"Keel RA, Schaeftlein A, Kloft C, Pope JS, Knauft RF, Muhlebach M, Nicolau DP, Kuti JL (2011) Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis. Antimicrob Agents Chemother 55(7):3393\u20133398. doi: 10.1128\/aac.01797-10","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"1876_CR69","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1016\/j.ijid.2009.10.002","volume":"14","author":"J Dotis","year":"2010","unstructured":"Dotis J, Iosifidis E, Ioannidou M, Roilides E (2010) Use of linezolid in pediatrics: a critical review. Int J Infect Dis 14(8):e638\u2013e648. doi: 10.1016\/j.ijid.2009.10.002","journal-title":"Int J Infect Dis"},{"issue":"7","key":"1876_CR70","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2165\/11319960-000000000-00000","volume":"49","author":"A Paolo Di","year":"2010","unstructured":"Di Paolo A, Malacarne P, Guidotti E, Danesi R, Del Tacca M (2010) Pharmacological issues of linezolid: an updated critical review. Clin Pharmacokinet 49(7):439\u2013447","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1876_CR71","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1517\/14728214.2010.517746","volume":"15","author":"H Grasemann","year":"2010","unstructured":"Grasemann H, Ratjen F (2010) Emerging therapies for cystic fibrosis lung disease. Expert Opin Emerg Drugs 15(4):653\u2013659. doi: 10.1517\/14728214.2010.517746","journal-title":"Expert Opin Emerg Drugs"},{"issue":"3","key":"1876_CR72","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/1753465810371107","volume":"4","author":"P Anderson","year":"2010","unstructured":"Anderson P (2010) Emerging therapies in cystic fibrosis. Ther Adv Respir Dis 4(3):177\u2013185. doi: 10.1177\/1753465810371107","journal-title":"Ther Adv Respir Dis"},{"issue":"4","key":"1876_CR73","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1172\/JCI6330","volume":"103","author":"RC Boucher","year":"1999","unstructured":"Boucher RC (1999) Status of gene therapy for cystic fibrosis lung disease. J Clin Invest 103(4):441\u2013445. doi: 10.1172\/jci6330","journal-title":"J Clin Invest"},{"issue":"4","key":"1876_CR74","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ppul.21028","volume":"44","author":"SD Sagel","year":"2009","unstructured":"Sagel SD, Sontag MK, Accurso FJ (2009) Relationship between antimicrobial proteins and airway inflammation and infection in cystic fibrosis. Pediatr Pulmonol 44(4):402\u2013409. doi: 10.1002\/ppul.21028","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"1876_CR75","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0952-7915(00)00187-4","volume":"13","author":"SM Travis","year":"2001","unstructured":"Travis SM, Singh PK, Welsh MJ (2001) Antimicrobial peptides and proteins in the innate defense of the airway surface. Curr Opin Immunol 13(1):89\u201395. doi: 10.1016\/s0952-7915(00)00187-4","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"1876_CR76","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/rr167","volume":"3","author":"MT Albrecht","year":"2002","unstructured":"Albrecht MT, Wang W, Shamova O, Lehrer RI, Schiller NL (2002) Binding of protegrin-1 to Pseudomonas aeruginosa and Burkholderia cepacia. Respir Res 3(1):18","journal-title":"Respir Res"},{"issue":"8","key":"1876_CR77","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.vaccine.2007.12.007","volume":"26","author":"G D\u00f6ring","year":"2008","unstructured":"D\u00f6ring G, Pier GB (2008) Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine 26(8):1011\u20131024. doi: 10.1016\/j.vaccine.2007.12.007","journal-title":"Vaccine"},{"issue":"3","key":"1876_CR78","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jcf.2011.01.002","volume":"10","author":"YP Lillquist","year":"2011","unstructured":"Lillquist YP, Cho E, Davidson AGF (2011) Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009. J Cyst Fibros 10(3):175\u2013180. doi: 10.1016\/j.jcf.2011.01.002","journal-title":"J Cyst Fibros"},{"issue":"4","key":"1876_CR79","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/thx.2009.121657","volume":"65","author":"F Ratjen","year":"2010","unstructured":"Ratjen F, Munck A, Kho P, Angyalosi G; ELITE Study Group (2010) Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 65(4):286\u2013291. doi: 10.1136\/thx.2009.121657","journal-title":"Thorax"},{"issue":"2","key":"1876_CR80","first-page":"141","volume":"108","author":"H Giugno","year":"2010","unstructured":"Giugno H, Casta\u00f1os C, Lubatti A, Pinheiro JL, Hern\u00e1ndez C, Gonz\u00e1lez Pena H (2010) Early antibiotic treatment for eradication of initial infection by Pseudomonas aeruginosa in patients with cystic fibrosis. Arch Argent Pediatr 108(2):141\u2013147","journal-title":"Arch Argent Pediatr"},{"issue":"3","key":"1876_CR81","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cct.2009.01.003","volume":"30","author":"MM Treggiari","year":"2009","unstructured":"Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW; EPIC Study Group (2009) Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study. Contemp Clin Trials 30(3):256\u2013268. doi: 10.1016\/j.cct.2009.01.003","journal-title":"Contemp Clin Trials"},{"key":"1876_CR82","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/ppul.21183","volume":"45","author":"N Mayer-Hamblett","year":"2010","unstructured":"Mayer-Hamblett N, Burns JL, Khan U, Retsch-Bogart G, Treggiari M, Ramsey BW (2010) Predictors of Pseudomonas aeruginosa recurrence in cystic fibrosis: results from the epic trial. Pediatr Pulmonol 45:326\u2013327","journal-title":"Pediatr Pulmonol"},{"key":"1876_CR83","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s10096-011-1483-8","volume":"31","author":"A Burkett","year":"2012","unstructured":"Burkett A, Vandemheen KL, Giesbrecht-Lewis T, Ramotar K, Ferris W, Chan F, Doucette S, Fergusson D, Aaron SD (2012) Persistency of Pseudomonas aeruginosa in sputum cultures and clinical outcomes in adult patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 31:1603\u20131610. doi: 10.1007\/s10096-011-1483-8","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"10","key":"1876_CR84","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1164\/rccm.200705-664OC","volume":"176","author":"PA Flume","year":"2007","unstructured":"Flume PA, O\u2019Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr, Willey-Courand DB, Bujan J, Finder J, Lester M, Quittell L, Rosenblatt R, Vender RL, Hazle L, Sabadosa K, Marshall B; Cystic Fibrosis Foundation, Pulmonary Therapies Committee (2007) Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 176(10):957\u2013969. doi: 10.1164\/rccm.200705-664OC","journal-title":"Am J Respir Crit Care Med"},{"key":"1876_CR85","volume-title":"Delineamento de formas farmac\u00eauticas","author":"ME Aulton","year":"2005","unstructured":"Aulton ME (2005) Delineamento de formas farmac\u00eauticas, 2nd edn. Artmed, Porto Alegre","edition":"2"},{"issue":"1\u20132","key":"1876_CR86","first-page":"69","volume":"63","author":"B Forbes","year":"2010","unstructured":"Forbes B, Asgharian B, Dailey LA, Ferguson D, Gerde P, Gumbleton M, Gustavsson L, Hardy C, Hassall D, Jones R, Lock R, Maas J, McGovern T, Pitcairn GR, Somers G, Wolff RK (2010) Challenges in inhaled product development and opportunities for open innovation. Adv Drug Deliv Rev 63(1\u20132):69\u201387. doi: 10.1016\/j.addr.2010.11.004","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"1876_CR87","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00003088-200544030-00004","volume":"44","author":"M Sakagami","year":"2005","unstructured":"Sakagami M, Byron PR (2005) Respirable microspheres for inhalation: the potential of manipulating pulmonary disposition for improved therapeutic efficacy. Clin Pharmacokinet 44(3):263\u2013277","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1876_CR88","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0169-409X(95)00113-L","volume":"19","author":"JS Patton","year":"1996","unstructured":"Patton JS (1996) Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev 19(1):3\u201336. doi: 10.1016\/0169-409x(95)00113-l","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"1876_CR89","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0378-5173(95)00104-Q","volume":"124","author":"XM Zeng","year":"1995","unstructured":"Zeng XM, Martin GP, Marriott C (1995) The controlled delivery of drugs to the lung. Int J Pharm 124(2):149\u2013164. doi: 10.1016\/0378-5173(95)00104-q","journal-title":"Int J Pharm"},{"issue":"9","key":"1876_CR90","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1128\/AAC.00411-10","volume":"54","author":"S Marchand","year":"2010","unstructured":"Marchand S, Gobin P, Brillault J, Baptista S, Adier C, Olivier J-C, Mimoz O, Couet W (2010) Aerosol therapy with colistin methanesulfonate: a biopharmaceutical issue illustrated in rats. Antimicrob Agents Chemother 54(9):3702\u20133707. doi: 10.1128\/aac.00411-10","journal-title":"Antimicrob Agents Chemother"},{"issue":"1\u20132","key":"1876_CR91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2010.03.017","volume":"392","author":"G Pilcer","year":"2010","unstructured":"Pilcer G, Amighi K (2010) Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm 392(1\u20132):1\u201319. doi: 10.1016\/j.ijpharm.2010.03.017","journal-title":"Int J Pharm"},{"issue":"6","key":"1876_CR92","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/ppul.21011","volume":"44","author":"T Bjarnsholt","year":"2009","unstructured":"Bjarnsholt T, Jensen P\u00d8, Fiandaca MJ, Pedersen J, Hansen CR, Andersen CB, Pressler T, Givskov M, H\u00f8iby N (2009) Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol 44(6):547\u2013558. doi: 10.1002\/ppul.21011","journal-title":"Pediatr Pulmonol"},{"issue":"Suppl 6","key":"1876_CR93","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0300-2896(11)70033-3","volume":"47","author":"M Vendrell Relat","year":"2011","unstructured":"Vendrell Relat M, Mu\u00f1oz Castro G, Sabater Talaverano G, De Gracia Rold\u00e1n J (2011) The future of inhaled antibiotic therapy. New products (El futuro de la antibioterapia inhalada. Nuevos productos). Arch Bronconeumol 47(Suppl 6):30\u201332","journal-title":"Arch Bronconeumol"},{"issue":"1\u20132","key":"1876_CR94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2010.12.040","volume":"406","author":"TC Carvalho","year":"2011","unstructured":"Carvalho TC, Peters JI, Williams RO 3rd (2011) Influence of particle size on regional lung deposition\u2014what evidence is there? Int J Pharm 406(1\u20132):1\u201310. doi: 10.1016\/j.ijpharm.2010.12.040","journal-title":"Int J Pharm"},{"issue":"4","key":"1876_CR95","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1513\/pats.200409-046TA","volume":"1","author":"J Heyder","year":"2004","unstructured":"Heyder J (2004) Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc Am Thorac Soc 1(4):315\u2013320. doi: 10.1513\/pats.200409-046TA","journal-title":"Proc Am Thorac Soc"},{"issue":"1\u20132","key":"1876_CR96","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0378-5173(02)00526-4","volume":"249","author":"AH Boer de","year":"2002","unstructured":"de Boer AH, Gjaltema D, Hagedoorn P, Frijlink HW (2002) Characterization of inhalation aerosols: a critical evaluation of cascade impactor analysis and laser diffraction technique. Int J Pharm 249(1\u20132):219\u2013231. doi: 10.1016\/s0378-5173(02)00526-4","journal-title":"Int J Pharm"},{"issue":"1","key":"1876_CR97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/02652040802083900","volume":"26","author":"J Emami","year":"2009","unstructured":"Emami J, Hamishehkar H, Najafabadi AR, Gilani K, Minaiyan M, Mahdavi H, Mirzadeh H, Fakhari A, Nokhodchi A (2009) Particle size design of PLGA microspheres for potential pulmonary drug delivery using response surface methodology. J Microencapsul 26(1):1\u20138. doi: 10.1080\/02652040802083900","journal-title":"J Microencapsul"},{"issue":"1","key":"1876_CR98","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/jps.21082","volume":"97","author":"F Mohamed","year":"2008","unstructured":"Mohamed F, van der Walle CF (2008) Engineering biodegradable polyester particles with specific drug targeting and drug release properties. J Pharm Sci 97(1):71\u201387. doi: 10.1002\/jps.21082","journal-title":"J Pharm Sci"},{"issue":"12","key":"1876_CR99","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1023\/B:PHAM.0000008051.94834.10","volume":"20","author":"LA Dailey","year":"2003","unstructured":"Dailey LA, Kleemann E, Wittmar M, Gessler T, Schmehl T, Roberts C, Seeger W, Kissel T (2003) Surfactant-free, biodegradable nanoparticles for aerosol therapy based on the branched polyesters, DEAPA-PVAL-g-PLGA. Pharm Res 20(12):2011\u20132020. doi: 10.1023\/b:pham.0000008051.94834.10","journal-title":"Pharm Res"},{"issue":"2","key":"1876_CR100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.addr.2008.09.006","volume":"61","author":"Y Cu","year":"2009","unstructured":"Cu Y, Saltzman WM (2009) Mathematical modeling of molecular diffusion through mucus. Adv Drug Deliv Rev 61(2):101\u2013114. doi: 10.1016\/j.addr.2008.09.006","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"1876_CR101","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.addr.2008.09.008","volume":"61","author":"RA Cone","year":"2009","unstructured":"Cone RA (2009) Barrier properties of mucus. Adv Drug Deliv Rev 61(2):75\u201385. doi: 10.1016\/j.addr.2008.09.008","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"1876_CR102","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1128\/IAI.73.6.3693-3701.2005","volume":"73","author":"TS Walker","year":"2005","unstructured":"Walker TS, Tomlin KL, Worthen GS, Poch KR, Lieber JG, Saavedra MT, Fessler MB, Malcolm KC, Vasil ML, Nick JA (2005) Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils. Infect Immun 73(6):3693\u20133701. doi: 10.1128\/iai.73.6.3693-3701.2005","journal-title":"Infect Immun"},{"issue":"13","key":"1876_CR103","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1016\/j.biomaterials.2008.12.076","volume":"30","author":"JS Suk","year":"2009","unstructured":"Suk JS, Lai SK, Wang Y-Y, Ensign LM, Zeitlin PL, Boyle MP, Hanes J (2009) The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. Biomaterials 30(13):2591\u20132597. doi: 10.1016\/j.biomaterials.2008.12.076","journal-title":"Biomaterials"},{"issue":"5","key":"1876_CR104","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1073\/pnas.0608611104","volume":"104","author":"SK Lai","year":"2007","unstructured":"Lai SK, O\u2019Hanlon DE, Harrold S, Man ST, Wang Y-Y, Cone R, Hanes J (2007) Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci U S A 104(5):1482\u20131487. doi: 10.1073\/pnas.0608611104","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1876_CR105","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1164\/ajrccm.162.5.9909009","volume":"162","author":"NN Sanders","year":"2000","unstructured":"Sanders NN, De Smedt SC, Van Rompaey E, Simoens P, De Baets F, Demeester J (2000) Cystic fibrosis sputum: a barrier to the transport of nanospheres. Am J Respir Crit Care Med 162(5):1905\u20131911","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"1876_CR106","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1023\/A:1015139527747","volume":"19","author":"NN Sanders","year":"2002","unstructured":"Sanders NN, Van Rompaey E, De Smedt SC, Demeester J (2002) On the transport of lipoplexes through cystic fibrosis sputum. Pharm Res 19(4):451\u2013456. doi: 10.1023\/a:1015139527747","journal-title":"Pharm Res"},{"issue":"16","key":"1876_CR107","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/sj.gt.3302968","volume":"14","author":"R Kushwah","year":"2007","unstructured":"Kushwah R, Oliver JR, Cao H, Hu J (2007) Nacystelyn enhances adenoviral vector-mediated gene delivery to mouse airways. Gene Ther 14(16):1243\u20131248. doi: 10.1038\/sj.gt.3302968","journal-title":"Gene Ther"},{"issue":"18","key":"1876_CR108","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/sj.gt.3301525","volume":"8","author":"S Ferrari","year":"2001","unstructured":"Ferrari S, Kitson C, Farley R, Steel R, Marriott C, Parkins DA, Scarpa M, Wainwright B, Evans MJ, Colledge WH, Geddes DM, Alton EW (2001) Mucus altering agents as adjuncts for nonviral gene transfer to airway epithelium. Gene Ther 8(18):1380\u20131386. doi: 10.1038\/sj.gt.3301525","journal-title":"Gene Ther"},{"issue":"1","key":"1876_CR109","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11095-009-9991-2","volume":"27","author":"Y Yang","year":"2010","unstructured":"Yang Y, Tsifansky MD, Wu C-J, Yang HI, Schmidt G, Yeo Y (2010) Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis. Pharm Res 27(1):151\u2013160. doi: 10.1007\/s11095-009-9991-2","journal-title":"Pharm Res"},{"issue":"6","key":"1876_CR110","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/bit.23046","volume":"108","author":"Y Yang","year":"2011","unstructured":"Yang Y, Tsifansky MD, Shin S, Lin Q, Yeo Y (2011) Mannitol-guided delivery of ciprofloxacin in artificial cystic fibrosis mucus model. Biotechnol Bioeng 108(6):1441\u20131449. doi: 10.1002\/bit.23046","journal-title":"Biotechnol Bioeng"},{"issue":"3","key":"1876_CR111","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejps.2010.03.020","volume":"40","author":"H Adi","year":"2010","unstructured":"Adi H, Young PM, Chan H-K, Agus H, Traini D (2010) Co-spray-dried mannitol\u2013ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. Eur J Pharm Sci 40(3):239\u2013247. doi: 10.1016\/j.ejps.2010.03.020","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"1876_CR112","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1128\/AAC.01744-10","volume":"55","author":"DE Geller","year":"2011","unstructured":"Geller DE, Flume PA, Griffith DC, Morgan E, White D, Loutit JS, Dudley MN (2011) Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob Agents Chemother 55(6):2636\u20132640. doi: 10.1128\/aac.01744-10","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"1876_CR113","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1586\/eri.11.131","volume":"9","author":"BM Assael","year":"2011","unstructured":"Assael BM (2011) Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. Expert Rev Anti Infect Ther 9(11):967\u2013973. doi: 10.1586\/eri.11.131","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"2","key":"1876_CR114","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2165\/11206940-000000000-00000","volume":"13","author":"GL Plosker","year":"2011","unstructured":"Plosker GL (2011) Aztreonam lysine for inhalation solution in cystic fibrosis: profile report. Paediatr Drugs 13(2):129\u2013131. doi: 10.2165\/11206940-000000000-00000","journal-title":"Paediatr Drugs"},{"key":"1876_CR115","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/CE.S11181","volume":"6","author":"S Kirkby","year":"2011","unstructured":"Kirkby S, Novak K, McCoy K (2011) Aztreonam (for inhalation solution) for the treatment of chronic lung infections in patients with cystic fibrosis: an evidence-based review. Core Evid 6:59\u201366","journal-title":"Core Evid"},{"issue":"14","key":"1876_CR116","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.2165\/10484070-000000000-00000","volume":"70","author":"GL Plosker","year":"2010","unstructured":"Plosker GL (2010) Aztreonam lysine for inhalation solution in cystic fibrosis. Drugs 70(14):1843\u20131855","journal-title":"Drugs"},{"key":"1876_CR117","first-page":"338","volume":"45","author":"SA McColley","year":"2010","unstructured":"McColley SA, Trapnell B, Kissner D, McKevitt M, Montgomery B, Rosen J; FTIS Study Group (2010) Fosfomycin\/tobramycin for inhalation (FTI): microbiological results of a phase 2 placebo-controlled trial in patients with cystic fibrosis and Pseudomonas aeruginosa. Pediatr Pulmonol 45:338","journal-title":"Pediatr Pulmonol"},{"key":"1876_CR118","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1089\/jamp.2010.0838","volume":"23","author":"JG Weers","year":"2010","unstructured":"Weers JG, Bell J, Chan HK, Cipolla D, Dunbar C, Hickey AJ, Smith IJ (2010) Pulmonary formulations: what remains to be done? J Aerosol Med Pulm Drug Deliv 23:S5\u2013S23. doi: 10.1089\/jamp.2010.0838","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"1","key":"1876_CR119","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/03639040903099769","volume":"36","author":"H Adi","year":"2010","unstructured":"Adi H, Young PM, Chan H-K, Salama R, Traini D (2010) Controlled release antibiotics for dry powder lung delivery. Drug Dev Ind Pharm 36(1):119\u2013126. doi: 10.3109\/03639040903099769","journal-title":"Drug Dev Ind Pharm"},{"issue":"4","key":"1876_CR120","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jcf.2006.10.010","volume":"6","author":"EM Westerman","year":"2007","unstructured":"Westerman EM, De Boer AH, Le Brun PPH, Touw DJ, Roldaan AC, Frijlink HW, Heijerman HGM (2007) Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study. J Cyst Fibros 6(4):284\u2013292. doi: 10.1016\/j.jcf.2006.10.010","journal-title":"J Cyst Fibros"},{"issue":"3","key":"1876_CR121","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1183\/09031936.02.00248102","volume":"20","author":"ME Hodson","year":"2002","unstructured":"Hodson ME, Gallagher CG, Govan JRW (2002) A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 20(3):658\u2013664. doi: 10.1183\/09031936.02.00248102","journal-title":"Eur Respir J"},{"issue":"4","key":"1876_CR122","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/thoraxjnl-2012-202059","volume":"68","author":"A Schuster","year":"2013","unstructured":"Schuster A, Haliburn C, D\u00f6ring G, Goldman MH; Freedom Study Group (2013) Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 68(4):344\u2013350. doi: 10.1136\/thoraxjnl-2012-202059","journal-title":"Thorax"},{"issue":"1\u20132","key":"1876_CR123","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ijpharm.2011.05.007","volume":"414","author":"TV Doan","year":"2011","unstructured":"Doan TV, Couet W, Olivier JC (2011) Formulation and in vitro characterization of inhalable rifampicin-loaded PLGA microspheres for sustained lung delivery. Int J Pharm 414(1\u20132):112\u2013117. doi: 10.1016\/j.ijpharm.2011.05.007","journal-title":"Int J Pharm"},{"issue":"1","key":"1876_CR124","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jconrel.2005.01.003","volume":"104","author":"RO Cook","year":"2005","unstructured":"Cook RO, Pannu RK, Kellaway IW (2005) Novel sustained release microspheres for pulmonary drug delivery. J Control Release 104(1):79\u201390. doi: 10.1016\/j.jconrel.2005.01.003","journal-title":"J Control Release"},{"issue":"3","key":"1876_CR125","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ijantimicag.2005.10.021","volume":"27","author":"G Rukholm","year":"2006","unstructured":"Rukholm G, Mugabe C, Azghani AO, Omri A (2006) Antibacterial activity of liposomal gentamicin against Pseudomonas aeruginosa: a time\u2013kill study. Int J Antimicrob Agents 27(3):247\u2013252. doi: 10.1016\/j.ijantimicag.2005.10.021","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"1876_CR126","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/jac\/dkh518","volume":"55","author":"C Mugabe","year":"2005","unstructured":"Mugabe C, Azghani AO, Omri A (2005) Liposome-mediated gentamicin delivery: development and activity against resistant strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients. J Antimicrob Chemother 55(2):269\u2013271. doi: 10.1093\/jac\/dkh518","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"1876_CR127","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/07373930600611877","volume":"24","author":"M-I R\u00e9","year":"2006","unstructured":"R\u00e9 M-I (2006) Formulating drug delivery systems by spray drying. Dry Technol 24(4):433\u2013446. doi: 10.1080\/07373930600611877","journal-title":"Dry Technol"},{"issue":"1","key":"1876_CR128","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1517\/14712598.4.1.35","volume":"4","author":"NK Varde","year":"2004","unstructured":"Varde NK, Pack DW (2004) Microspheres for controlled release drug delivery. Expert Opin Biol Ther 4(1):35\u201351. doi: 10.1517\/14712598.4.1.35","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"1876_CR129","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/jps.22272","volume":"100","author":"W Liu","year":"2011","unstructured":"Liu W, Yang X-L, Ho WS (2011) Preparation of uniform-sized multiple emulsions and micro\/nano particulates for drug delivery by membrane emulsification. J Pharm Sci 100(1):75\u201393. doi: 10.1002\/jps.22272","journal-title":"J Pharm Sci"},{"issue":"2","key":"1876_CR130","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.colsurfb.2007.10.005","volume":"62","author":"ML Manca","year":"2008","unstructured":"Manca ML, Mourtas S, Dracopoulos V, Fadda AM, Antimisiaris SG (2008) PLGA, chitosan or chitosan-coated PLGA microparticles for alveolar delivery? A comparative study of particle stability during nebulization. Colloids Surf B Biointerfaces 62(2):220\u2013231. doi: 10.1016\/j.colsurfb.2007.10.005","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"2","key":"1876_CR131","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s10924-011-0290-8","volume":"19","author":"S Ravindra","year":"2011","unstructured":"Ravindra S, Varaprasad K, Narayana Reddy N, Vimala K, Mohana Raju K (2011) Biodegradable microspheres for controlled release of an antibiotic ciprofloxacin. J Polym Environ 19(2):413\u2013418. doi: 10.1007\/s10924-011-0290-8","journal-title":"J Polym Environ"},{"issue":"1","key":"1876_CR132","first-page":"2591","volume":"6","author":"S Mura","year":"2011","unstructured":"Mura S, Hillaireau H, Nicolas J, Le Droumaguet B, Gueutin C, Zanna S, Tsapis N, Fattal E (2011) Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu-3 cells. Int J Nanomedicine 6(1):2591\u20132605. doi: 10.2147\/IJN.S24552","journal-title":"Int J Nanomedicine"},{"issue":"10","key":"1876_CR133","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.biomaterials.2008.12.044","volume":"30","author":"Y Yang","year":"2009","unstructured":"Yang Y, Bajaj N, Xu P, Ohn K, Tsifansky MD, Yeo Y (2009) Development of highly porous large PLGA microparticles for pulmonary drug delivery. Biomaterials 30(10):1947\u20131953. doi: 10.1016\/j.biomaterials.2008.12.044","journal-title":"Biomaterials"},{"issue":"8","key":"1876_CR134","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1023\/A:1007527204887","volume":"17","author":"P O\u2019Hara","year":"2000","unstructured":"O\u2019Hara P, Hickey AJ (2000) Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm Res 17(8):955\u2013961. doi: 10.1023\/a:1007527204887","journal-title":"Pharm Res"},{"issue":"1\u20132","key":"1876_CR135","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijpharm.2006.10.005","volume":"333","author":"S Giovagnoli","year":"2007","unstructured":"Giovagnoli S, Blasi P, Schoubben A, Rossi C, Ricci M (2007) Preparation of large porous biodegradable microspheres by using a simple double-emulsion method for capreomycin sulfate pulmonary delivery. Int J Pharm 333(1\u20132):103\u2013111. doi: 10.1016\/j.ijpharm.2006.10.005","journal-title":"Int J Pharm"},{"issue":"4","key":"1876_CR136","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1002\/jps.21946","volume":"99","author":"V Gupta","year":"2010","unstructured":"Gupta V, Rawat A, Ahsan F (2010) Feasibility study of aerosolized prostaglandin E(1) microspheres as a noninvasive therapy for pulmonary arterial hypertension. J Pharm Sci 99(4):1774\u20131789. doi: 10.1002\/jps.21946","journal-title":"J Pharm Sci"},{"issue":"2","key":"1876_CR137","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ejpb.2007.05.011","volume":"68","author":"CA Ventura","year":"2008","unstructured":"Ventura CA, Tommasini S, Crupi E, Giannone I, Cardile V, Musumeci T, Puglisi G (2008) Chitosan microspheres for intrapulmonary administration of moxifloxacin: Interaction with biomembrane models and in vitro permeation studies. Eur J Pharm Biopharm 68(2):235\u2013244. doi: 10.1016\/j.ejpb.2007.05.011","journal-title":"Eur J Pharm Biopharm"},{"issue":"11","key":"1876_CR138","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1248\/bpb.27.1717","volume":"27","author":"KPR Chowdary","year":"2004","unstructured":"Chowdary KPR, Rao YS (2004) Mucoadhesive microspheres for controlled drug delivery. Biol Pharm Bull 27(11):1717\u20131724. doi: 10.1248\/bpb.27.1717","journal-title":"Biol Pharm Bull"},{"issue":"4","key":"1876_CR139","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1099\/00222615-43-4-300","volume":"43","author":"HY Chen","year":"1995","unstructured":"Chen HY, Yuan M, Livermore DM (1995) Mechanisms of resistance to \u03b2-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993. J Med Microbiol 43(4):300\u2013309. doi: 10.1099\/00222615-43-4-300","journal-title":"J Med Microbiol"},{"issue":"10","key":"1876_CR140","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1023\/A:1012296604685","volume":"18","author":"R Sharma","year":"2001","unstructured":"Sharma R, Saxena D, Dwivedi AK, Misra A (2001) Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm Res 18(10):1405\u20131410. doi: 10.1023\/a:1012296604685","journal-title":"Pharm Res"},{"issue":"5","key":"1876_CR141","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s10544-011-9550-6","volume":"13","author":"CA Ventura","year":"2011","unstructured":"Ventura CA, Cannav\u00e0 C, Stancanelli R, Paolino D, Cosco D, La Mantia A, Pignatello R, Tommasini S (2011) Gemcitabine-loaded chitosan microspheres. Characterization and biological in vitro evaluation. Biomed Microdevices 13(5):799\u2013807. doi: 10.1007\/s10544-011-9550-6","journal-title":"Biomed Microdevices"},{"issue":"2","key":"1876_CR142","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/jps.22777","volume":"101","author":"RA Tuli","year":"2012","unstructured":"Tuli RA, Dargaville TR, George GA, Islam N (2012) Polycaprolactone microspheres as carriers for dry powder inhalers: effect of surface coating on aerosolization of salbutamol sulfate. J Pharm Sci 101(2):733\u2013745. doi: 10.1002\/jps.22777","journal-title":"J Pharm Sci"},{"issue":"3","key":"1876_CR143","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ejpb.2005.09.008","volume":"62","author":"DO Corrigan","year":"2006","unstructured":"Corrigan DO, Healy AM, Corrigan OI (2006) Preparation and release of salbutamol from chitosan and chitosan co-spray dried compacts and multiparticulates. Eur J Pharm Biopharm 62(3):295\u2013305. doi: 10.1016\/j.ejpb.2005.09.008","journal-title":"Eur J Pharm Biopharm"},{"issue":"3","key":"1876_CR144","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.powtec.2008.02.015","volume":"187","author":"TP Learoyd","year":"2008","unstructured":"Learoyd TP, Burrows JL, French E, Seville PC (2008) Modified release of beclometasone dipropionate from chitosan-based spray-dried respirable powders. Powder Technol 187(3):231\u2013238. doi: 10.1016\/j.powtec.2008.02.015","journal-title":"Powder Technol"},{"issue":"1\u20133","key":"1876_CR145","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0168-3659(02)00034-2","volume":"80","author":"M Sakagami","year":"2002","unstructured":"Sakagami M, Kinoshita W, Sakon K, Sato J, Makino Y (2002) Mucoadhesive beclomethasone microspheres for powder inhalation: their pharmacokinetics and pharmacodynamics evaluation. J Control Release 80(1\u20133):207\u2013218. doi: 10.1016\/s0168-3659(02)00034-2","journal-title":"J Control Release"},{"issue":"1\u20132","key":"1876_CR146","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijpharm.2009.07.020","volume":"380","author":"S Harsha","year":"2009","unstructured":"Harsha S, Chandramouli R, Rani S (2009) Ofloxacin targeting to lungs by way of microspheres. Int J Pharm 380(1\u20132):127\u2013132. doi: 10.1016\/j.ijpharm.2009.07.020","journal-title":"Int J Pharm"},{"issue":"6","key":"1876_CR147","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jiec.2008.05.004","volume":"14","author":"Y-I Jeong","year":"2008","unstructured":"Jeong Y-I, Kim D-G, Seo D-H, Jang M-K, Nah J-W (2008) Multiparticulation of ciprofloxacin HCl-encapsulated chitosan microspheres using poly(dl-lactide-co-glycolide). J Ind Eng Chem 14(6):747\u2013751. doi: 10.1016\/j.jiec.2008.05.004","journal-title":"J Ind Eng Chem"},{"issue":"1\u20132","key":"1876_CR148","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijpharm.2004.01.033","volume":"275","author":"K Dillen","year":"2004","unstructured":"Dillen K, Vandervoort J, Van den Mooter G, Verheyden L, Ludwig A (2004) Factorial design, physicochemical characterisation and activity of ciprofloxacin-PLGA nanoparticles. Int J Pharm 275(1\u20132):171\u2013187. doi: 10.1016\/j.ijpharm.2004.01.033","journal-title":"Int J Pharm"},{"issue":"1","key":"1876_CR149","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0168-3659(95)00017-3","volume":"35","author":"EA Poyner","year":"1995","unstructured":"Poyner EA, Alpar HO, Almeida AJ, Gamble MD, Brown MRW (1995) A comparative study on the pulmonary delivery of tobramycin encapsulated into liposomes and PLA microspheres following intravenous and endotracheal delivery. J Control Release 35(1):41\u201348. doi: 10.1016\/0168-3659(95)00017-3","journal-title":"J Control Release"},{"key":"1876_CR150","unstructured":"Cystic Fibrosis Foundation (2012) Patient registry. Annual data report 2011. Available online at: http:\/\/www.cff.org\/UploadedFiles\/research\/ClinicalResearch\/2011-Patient-Registry.pdf . Accessed 11 March 2013"},{"key":"1876_CR151","unstructured":"Cystic Fibrosis Foundation (2012) Drug development pipeline. Available online at: http:\/\/www.cff.org\/research\/DrugDevelopmentPipeline\/ . Accessed 8 January 2013"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-013-1876-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-013-1876-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-013-1876-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T19:16:04Z","timestamp":1644952564000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-013-1876-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,26]]},"references-count":151,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["1876"],"URL":"https:\/\/doi.org\/10.1007\/s10096-013-1876-y","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,26]]}}}